The global impact of Precision Medicine Group.
As it happens.
Impact, observations, and insights on the evolving healthcare landscape.
Recent AI applications rely heavily on predictive AI, which harnesses historical data to make predictions and recommendations for the future. But what is really propelling the industry forward is generative AI, which uses models or algorithms to create various types of content using learned patterns based on the data on which it was trained.
SVP/Chief Architect Tobias Guennel outlines how generative AI will speed up clinical trial execution as sponsors integrate AI-enabled technologies into their day-to-day workflows.
Sofia Baig, President of Clinical Solutions at Precision, opens up about her career, the challenges she overcame, and the ways this journey shaped her as leader, a mother, and a trend setter.
This article was originally published on This Month in Transformative Medicine on October 17, 2023
The current standard of cancer care has saved many lives, but these methods often come with incredibly difficult side effects. Advancements in technology have brought new options to cancer care that hope to provide meaningful outcomes while minimizing the impact to the patient’s quality of life.
In this white paper Anshul Mangal, President of Project Farma (PF) & Precision ADVANCE, and Sumit Verma, Co-founder and Partner at Orchestra Life Sciences, discuss the power and potential of radioligand therapies and its impact on the treatment of a number of cancers.
Precision will be at HLTH 2023, October 8 – 11, in Las Vegas, NV. Connect with our team of experts as they lead meaningful discussions and attend networking events focused on innovation and transformation for better patient health and treatment outcomes.
Connect with one our experts!
In the rapidly evolving landscape of advanced therapies, allogeneic cell therapies have emerged as a promising avenue for addressing various disorders, including hematological malignancies, neurological conditions, and autoimmune or inflammatory diseases. With a number of clinical trials underway to evaluate their efficacy, allogeneic cell therapies hold significant potential in reshaping the way we approach treating numerous diseases.
In this white paper, Anshul Mangal, President of Project Farma & Precision ADVANCE and John Khoury, Executive Vice President of Project Farma (PF), discuss the growth of the allogeneic cell therapy sector and its impact on patient access.
Precision will be at this year’s Association for Value-Based Cancer Care 2023 Educational Summit & Program, October 18 – 20, NYC, NY. This exclusive invitational forum provides invaluable time with more than 200 diverse experts representing every stakeholder of the cancer care ecosystem.
Don’t miss an opportunity to celebrate groundbreaking science and network with industry leaders!
Speaking Engagements
Detailed descriptions for each speaking engagement are included below.
You can register for the Association for Value-Based Cancer Care 2023 Educational Summit & Program below:
Precision will be at this year’s Meeting on the Mesa, October 10-12, 2023, in Carlsbad, CA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for cell and gene therapies.
Connect with our Advanced Therapy experts
You can register for Meeting on the Mesa below:
Precision is honored to be a sponsor of this year’s Endpoints 11 taking place on September 20, 2023, in Boston, MA. Join a select group of industry leaders for this year’s awards gala as we gather at the State Room in Downtown Boston for an evening of dinner, drinks and networking to meet the future of biotech.
Connect with our Advanced Therapy experts!
CLICK HERE to reserve your spot.
Precision will be at this year’s 4th Annual Gene Therapy Immunogenicity Summit, September 5 – 7, 2023, in Boston, MA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the development for cell and gene therapies.
Connect with our Advanced Therapy experts!
You can register for the 4th Annual Gene Therapy Immunogenicity Summit below:
The concept of optimizing CGT value propositions begs the question of what is reasonable when it comes to breakthrough science and unprecedented therapeutic solutions. Can a $5 million price tag be justified? What about $10 million?
This white paper is based on a webinar convened by PRECISIONadvisors, focusing on cell and gene therapy (CGT) pricing. The webinar featured two in-house experts from the PRECISIONadvisors Global Pricing & Market Access practice: Richard Macaulay, Senior Vice President and David Carr, Senior Director.